Tiova Rotacap: Advanced COPD Symptom Control and Bronchodilation
Tiova Rotacap
| Product dosage: 18 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | $1.50 | $45.00 (0%) | 🛒 Add to cart |
| 60 | $1.30 | $90.00 $78.00 (13%) | 🛒 Add to cart |
| 90 | $0.96
Best per cap | $135.00 $86.00 (36%) | 🛒 Add to cart |
Synonyms | |||
Tiova Rotacap is a high-efficacy, long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Its primary active ingredient, Tiotropium Bromide, functions as a bronchodilator by selectively inhibiting muscarinic receptors in the airway smooth muscle, leading to sustained relaxation and improved airflow. This formulation is delivered via the Rotahaler® device, ensuring deep lung deposition for optimal therapeutic effect. It is designed for daily management to reduce exacerbations, improve exercise tolerance, and enhance overall quality of life for patients with obstructive airway diseases.
Features
- Contains Tiotropium Bromide IP 18mcg per capsule
- Delivered via a breath-activated Rotahaler® device for efficient pulmonary deposition
- Dry powder inhaler (DPI) formulation, eliminating the need for propellants
- Pre-measured single-dose capsules ensure consistent dosage accuracy
- Designed for once-daily dosing to support adherence and simplify treatment regimens
- Stable at room temperature with a prolonged shelf life
Benefits
- Provides 24-hour bronchodilation from a single dose, ensuring round-the-clock symptom control
- Significantly reduces the frequency of COPD exacerbations and hospitalizations
- Improves lung function parameters (FEV1) and exercise capacity
- Enhances overall quality of life by reducing breathlessness and nighttime symptoms
- Minimizes the need for rescue medications through sustained action
- User-friendly device design supports correct inhalation technique and treatment compliance
Common use
Tiova Rotacap is routinely prescribed for the long-term maintenance treatment of airflow obstruction in patients diagnosed with chronic obstructive pulmonary disease (COPD). It is not indicated for the relief of acute bronchospasm but is used prophylactically to manage chronic symptoms. It is often part of a comprehensive management plan that may include other bronchodilators, inhaled corticosteroids, pulmonary rehabilitation, and smoking cessation support. Its use is common in moderate to severe COPD where persistent symptoms and recurrent exacerbations impact daily functioning.
Dosage and direction
The recommended dosage for Tiova Rotacap is the inhalation of the contents of one capsule (18 mcg) once daily, at the same time each day, using the Rotahaler® device. It should not be used more than once in a 24-hour period. To administer, place the capsule in the Rotahaler®, pierce it by twisting the device, exhale fully away from the mouthpiece, place lips tightly around the mouthpiece, inhale deeply and hold breath for up to 10 seconds if possible. Remove the device from the mouth and exhale slowly. The capsule should be discarded after use; it is for oral inhalation only and must not be swallowed.
Precautions
Patients should be advised that Tiova Rotacap is not a rescue medication and is not intended for the treatment of acute episodes of bronchospasm. Immediate medical attention should be sought if sudden breathing problems occur. Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, or severe renal impairment (creatinine clearance ≤50 mL/min). Patients should be instructed on proper inhalation technique to ensure optimal drug delivery. Eye pain or discomfort, blurred vision, visual halos, or colored images in association with red eyes from conjunctival congestion and corneal edema may be signs of acute narrow-angle glaucoma.
Contraindications
Tiova Rotacap is contraindicated in patients with a known hypersensitivity to tiotropium bromide, atropine or its derivatives, such as ipratropium or oxitropium, or to any component of the product. It should not be used for the initial treatment of acute episodes of bronchospasm where a rapid short-acting bronchodilator is required.
Possible side effects
Common side effects may include dry mouth, constipation, vomiting, dyspepsia, abdominal pain, headache, dizziness, cough, pharyngitis, rhinitis, sinusitis, and urinary retention. Less frequently, patients may experience tachycardia, palpitations, blurred vision, glaucoma, urinary difficulty, and paradoxical bronchospasm. Allergic reactions such as skin rash, itching, angioedema, and anaphylaxis are rare but possible. Patients should report any persistent or severe side effects to their healthcare provider.
Drug interaction
Concomitant use with other anticholinergic-containing drugs (e.g., ipratropium, aclidinium) may potentiate anticholinergic adverse effects and is not recommended. Caution is advised when used with drugs that are excreted renally or that may affect renal function. No clinically significant pharmacokinetic drug interactions have been observed with commonly co-administered drugs such as sympathomimetic bronchodilators, methylxanthines, oral or inhaled steroids, but pharmacodynamic interactions are possible. Always inform the physician of all current medications.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Do not double the dose to make up for a missed one.
Overdose
Overdose may lead to exaggerated anticholinergic effects such as dry mouth, visual disturbances, tachycardia, cardiac arrhythmias, constipation, difficulty in micturition, and central nervous system effects including anxiety, restlessness, and confusion. Treatment is symptomatic and supportive. In severe cases, ECG monitoring may be required. Since tiotropium is predominantly excretely renally, attention to renal function is advised.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep the capsules in the blister strips until immediately before use to protect from humidity. Do not store in a bathroom or near a sink. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for any health-related decisions or before starting any new therapy. Do not disregard or delay seeking professional medical advice because of something you have read here. The efficacy and safety profile may vary based on individual patient factors and clinical context.
Reviews
(Note: Simulated expert/clinical feedback based on therapeutic profile)
Clinical studies and post-marketing surveillance indicate that Tiova Rotacap is highly effective in improving lung function and reducing exacerbation rates in COPD patients. Pulmonologists frequently note its once-daily convenience and reliable 24-hour bronchodilation, which supports patient adherence. Users often report a significant reduction in breathlessness and an improved ability to perform daily activities. Some patients mention dry mouth as a manageable side effect. Overall, it is regarded as a cornerstone maintenance therapy in COPD management protocols, particularly valued for its sustained action and well-established safety profile.